ISIN | LU2207278669 |
---|---|
Valor Number | 114371863 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 84.25 USD | 16.04.2025 |
---|---|---|
Previous Price * | 85.10 USD | 15.04.2025 |
52 Week High * | 97.97 USD | 16.07.2024 |
52 Week Low * | 81.01 USD | 08.04.2025 |
NAV * | 84.25 USD | 16.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 73,970,946 | |
Unit/Share Assets *** | 1,720 | |
Trading Information SIX |
YTD Performance | -2.89% |
31.12.2024 - 16.04.2025
31.12.2024 16.04.2025 |
---|---|---|
YTD Performance (in CHF) | -13.01% |
31.12.2024 - 16.04.2025
31.12.2024 16.04.2025 |
1 month | -5.78% |
17.03.2025 - 16.04.2025
17.03.2025 16.04.2025 |
3 months | -7.91% |
16.01.2025 - 16.04.2025
16.01.2025 16.04.2025 |
6 months | -9.20% |
16.10.2024 - 16.04.2025
16.10.2024 16.04.2025 |
1 year | -6.03% |
16.04.2024 - 16.04.2025
16.04.2024 16.04.2025 |
2 years | -15.75% |
06.07.2023 - 16.04.2025
06.07.2023 16.04.2025 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Intra-Cellular Therapies Inc | 4.79% | |
---|---|---|
Hikma Pharmaceuticals PLC | 3.88% | |
Ambu AS Class B | 3.86% | |
DexCom Inc | 3.73% | |
Abbott Laboratories | 3.73% | |
Sandoz Group AG Registered Shares | 3.63% | |
Penumbra Inc | 3.60% | |
Amplifon SpA Az nom Post Frazionamento | 3.56% | |
Revvity Inc | 3.54% | |
Demant AS | 3.53% | |
Last data update | 31.01.2025 |
TER *** | 2.22% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 2.22% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |